



233284

00-0000000000

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at . Please contact CVS/Caremark at 1-888-413-2723 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of the medication.

Patient Name: Patient ID: Patient Group No: Physician Office Address:			_ Date: Patient Date Of Birth:	6/1	6/19/2025				
		NPI#:	Patient Phone:		Physician Name: Specialty: Physician Office Telephone				
					., .				
Dru	g Name (specify drug)								
Quantity: Route of Administration: Diagnosis:		Frequency:	Expected Length of Therapy:	trength:	_				
Cor									
Ple :	ase check the appropriate What is the diagnosis?	e answer for each applica	ble question.						
	Breast cancer (If chec	cked, go to 2)							
	Other, please specify. (If checked, no further questions)								
2.	Is the request for a cont	nuation of therapy with the	requested drug?		Y		N		
3.	Is there evidence of una	cceptable toxicity while on t	he current regimen?		Y		N		
4.	Is there evidence of dise	ease progression while on th	ne current regimen?		Y		N		
5.	Is the disease endocrine	e-resistant?			Y		N		
6.	Does the patient have a please attach laboratory	documented PIK3CA mutatest results confirming mutatest	tion? ACTION REQUIRED: If Yes	5,					
	Yes (If checked, go to	7)							
	No (If checked, no fur	ther questions)							
	Unknown (If checked,	no further questions)							
	ACTION REQUIRED:	Submit supporting docume	ntation						
7.		mone receptor (HR) status? ults of hormone receptor (HI	? ACTION REQUIRED: Please at R) status.	ttach					
	HR-Positive (If checke	ed, go to 8)							
	HR-Negative (If checked, no further questions)								
	Unknown (If checked,	no further questions)							
	ACTION REQUIRED:	Submit supporting docume	ntation						
8.	What is the human epid- ACTION REQUIRED: P growth factor receptor 2	lease attach chart note(s) o	r 2 (HER2) status of the disease? r test results of human epidermal	>					
	HER2-Positive (If che	cked, no further questions)							

and t	est that the medication requested is medically necessary for this patient. I further attest that the informat true, and that the documentation supporting this information is available for review if requested by the class		
10.	Will the requested drug be used in combination with palbociclib (Ibrance) and fulvestrant (Faslodex)?	Υ 🔲	N 🗆
	Metastatic disease (If checked, go to 10) Other, please specify. (If checked, no further questions)		
	Recurrent disease (If checked, go to 10)		
9.	What is the clinical setting in which the requested drug will be used? Locally advanced disease (If checked, go to 10)		
	Unknown (If checked, no further questions) ACTION REQUIRED: Submit supporting documentation		
	HER2-Negative (If checked, go to 9)		

Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.